Back to mobile site
Get it on Google Play

Tonix presents phase 1 data for Lyme disease prevention drug TNX-4800

March 31, 2026 7:01 AM EDT Send to a Friend
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented phase 1 clinical trial data for TNX-4800, a monoclonal antibody designed to prevent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login